Graft engineering using ex vivo methods to limit GVHD: Fludarabine treatment generates superior GVL effects in allogeneic BMT

Experimental Hematology

Volumn 34, Issue 7, 2006, Pages 895-904

  Li, Jian Ming ^a   Giver, Cynthia R ^a   Waller, Edmund K ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; PSORALEN;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; BLOOD SAMPLING; BONE MARROW; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; DONOR; FLOW CYTOMETRY; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUVA; RADIATION DOSE; RECIPIENT; SCORING SYSTEM; SPLEEN CELL; T CELL DEPLETION; TISSUE ENGINEERING;

ANIMALS; BONE MARROW TRANSPLANTATION; FLOW CYTOMETRY; GRAFT VS LEUKEMIA EFFECT; MICE; MICE, INBRED C57BL; SPLEEN; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

MURINAE;

EID: 33745184914     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.03.008     Document Type: Article

References (42)

1. + T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 8 (2002) 625-632
2. Fowler D.H., and Gress R.E. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 38 (2000) 221-234
3. Devine S.M., Adkins D.R., Khoury H., et al. Recent advances in allogeneic hematopoietic stem-cell transplantation. J Lab Clin Med 141 (2003) 7-32
4. + T-cell-depleted graft. Bone Marrow Transplant 31 (2003) 121-128
5. Robin M., Guardiola P., Dombret H., et al. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality. Bone Marrow Transplant 31 (2003) 877-887
6. Kim Y.M., Sachs T., Asavaroengchai W., Bronson R., and Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 111 (2003) 659-669
7. Krijanovski O.I., Hill G.R., Cooke K.R., et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 94 (1999) 825-831
8. Porter D.L., Stadtmauer E.A., and Lazarus H.M. "GVHD": graft-versus-host disease or graft-versus-Hodgkin's disease? an old acronym with new meaning. Bone Marrow Transplant 31 (2003) 739-746
9. Teshima T., Hill G.R., Pan L., et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 104 (1999) 317-325
10. Yang Y.G., Qi J., Wang M.G., and Sykes M. Donor-derived interferon γ separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood 99 (2002) 4207-4215
11. Waller E.K., Ship A.M., Mittelstaedt S., et al. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. Blood 94 (1999) 3222-3233
12. Truitt R.L., Johnson B.D., Hanke C., Talib S., and Hearst J.E. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 163 (1999) 5145-5156
13. Giver C.R., Montes R.O., Mittestaedt S., et al. Ex-vivo fludarabine exposure inhibits GvHD activity of allogeneic T-cells while preserving GvL effects. Biol Blood Marrow Transplant 9 (2003) 616-632
14. Roback J.D., Hossain M.S., Lezhava L., et al. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation. J Immunol 171 (2003) 6023-6031
15. Johnson S., Smith A.G., Loffler H., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347 (1996) 1432-1438
16. Keating M.J., Kantarjian H., Talpaz M., et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74 (1989) 19-25
17. Priebe T., Platsoucas C.D., Seki H., Fox F.E., and Nelson J.A. Purine nucleoside modulation of functions of human lymphocytes. Cell Immunol 129 (1990) 321-328
18. Ship A.M., and Waller E.K. Clinical use of irradiated donor lymphocytes in bone marrow transplantation. Cancer Treat Res 101 (1999) 267-282
19. Waller E.K., and Boyer M. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells. Bone Marrow Transplant 25 Suppl 2 (2000) S20-S24
20. Lin L., Cook D.N., Wiesehahn G.P., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37 (1997) 423-435
21. Laskin J.D., Mermelstein F.H., Heindel N.D., and Ron Y. Selective inactivation of lymphocytes after psoralen/ultraviolet light (PUVA) treatment without affecting systemic immune responses. J Leukoc Biol 54 (1993) 138-144
22. Johnson R., Staiano-Coico L., Austin L., et al. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 63 (1996) 566-571
23. Mielke V., Staib G., and Sterry W. Systemic treatment for cutaneous lymphomas. Recent Results Cancer Res 139 (1995) 403-408
24. Greinix H.T., Volc-Platzer B., Rabitsch W., et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 92 (1998) 3098-3104
25. Dall'Amico R., Rossetti F., Zulian F., et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 97 (1997) 848-854
26. Perez M., Edelson R., Laroche L., and Berger C. Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. J Invest Dermatol 92 (1989) 669-676
27. Grass J.A., Wafa T., Reames A., et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 93 (1999) 3140-3147
28. + T-cell line with potent in vivo graft-versus-leukemia properties. Blood 89 (1997) 3477-3485
29. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88 (1996) 3230-3239
30. Blazar B.R., Korngold R., and Vallera D.A. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 157 (1997) 79-109
31. + T cells do not induce graft-versus-host disease. J Clin Invest 112 (2003) 101-108
32. + hematopoietic stem cells. Blood 83 (1994) 3758-3779
33. Li J.M., and Waller E.K. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 10 (2004) 540-551
34. Kornblau S.M., Stiouf I., Snell V., et al. Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Cancer Res 61 (2001) 3355-3360
35. Hossain M.S., Roback J.D., Lezhava L., Hillyer C.D., and Waller E.K. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 11 (2005) 169-180
36. Giver C.R., Li J.M., Hossain M.S., Lonial S., and Waller E.K. Reconstructing immunity after allogeneic transplantation. Immunol Res 29 (2004) 269-282
37. Chen B.J., Cui X., Sempowski G.D., Liu C., and Chao N.J. Transfer of allogeneic CD62L memory T cells without graft-versus-host disease. Blood 103 (2004) 1534-1541
38. Sondel P.M., Buhtoiarov I.N., and DeSantes K. Pleasant memories: remembering immune protection while forgetting about graft-versus-host disease. J Clin Invest 112 (2003) 25-27
39. + naive T cells: potential for adoptive immunotherapy and allodepletion. Blood 104 (2004) 2403-2409
40. Yu X.Z., Bidwell S.J., Martin P.J., and Anasetti C. Anti-CD3 ε F(ab′)2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens. J Immunol 166 (2001) 5835-5839
41. Zeder K., Waller E.K., Redei I., et al. Impact of donor lymphocyte infusion for hematological malignancy relapsed after allogeneic bone marrow transplantation. Cancer Res Ther Control 5 (1998) 221-228
42. Waller E.K., Langston A., Lonial S., et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 9 (2003) 460-471